Publication | Closed Access

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

Breast OncologyOncologyPharmacologyImmune Checkpoint InhibitorBreast CancerPharmacotherapyAnti-cancer AgentCancer TreatmentPhase 1B–2MedicineHer2-positive Breast Cancer